Everyone’s worried about new drug tariffs—but they’re actually boosting U.S. Contract Development and Manufacturing Organizations (CDMOs). With tariffs driving up the cost of China-sourced APIs and packaging, American CDMOs with local supply chains are suddenly faster, higher quality, and even cheaper. For private equity investors, these “tariff-resistant” networks are a solid opportunity.
Tariffs Are Good?! Why U.S. Drug Manufacturers Are the Real Winners
Next
Next